Drug maker Lupin today said it has received final approval from the US drug regulator for marketing its Levetiractam tablets, which is used in the treatment of epilepsy.
In a filing to the Bombay Stock Exchange, the company said that its US subsidiary Lupin Pharmaceuticals Inc has received final approval from the United States Food and Drug Agency (USFDA) for its Levetiractam tablets under the abbreviated new drug application.
The approved tablets are in the capacity of 250, 500, 750 and 1,000 mg, the company said.
Lupin's Levetiractam tablets are the generic equivalent to Keppra, a brand manufactured by UCB Pharmaceuticals Inc.
Levetiractam is an anticonvulsant medication used to treat epilepsy. Along with other anticonvulsants like gabapentin, it is also sometimes used to treat neuropathic pain.
Shares of Lupin surged 2.4 per cent from its previous close and were trading at Rs 597 in the afternoon trade on the BSE.
